EUVIMEDEUVIMED entdecken
Open Access

Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study

Brandon M Podyma iD, Marissa Lightbourne, Rebecca J Brown iD

Journal of the Endocrine Society · 02.11.2026 · 10 (12)

DOI: 10.1210/jendso/bvag248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 07.11.2026. Verfasst von Brandon M Podyma und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Lipodystrophy syndromes are rare disorders of abnormal fat distribution and metabolic disease. The only approved therapy for generalized lipodystrophy is recombinant leptin (metreleptin), which is not approved for partial lipodystrophy. Recent data suggest efficacy of glucagon-like peptide-1 receptor agonists and glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide (GIP) dual agonists (collectively referred to as incretins) to treat complications of lipodystrophy.

Objective

To compare metabolic outcomes of incretin therapies vs metreleptin in partial lipodystrophy.

Design

Retrospective review of patients who received metreleptin as part of a clinical trial and incretins during routine care under a natural history study.

Setting

NIH Clinical Center. Patients Twelve female patients with partial lipodystrophy, aged 16-85 years. All but 1 patient had diabetes.

Intervention

Eleven patients with partial lipodystrophy were treated with metreleptin (mean duration 104 ± 38 months) before switching to incretin therapy (duration 32 ± 13 months). A twelfth patient took metreleptin and an incretin concurrently. Main outcome measures Outcome measures included hemoglobin A1c, insulin dose, Matsuda index, insulinogenic index, disposition index, fasting glucose and insulin, homeostatic model of beta cell function (HOMA-B), homeostatic model assessment of insulin resistance (HOMA-IR), weight, lipids, liver elastography, and liver steatosis.

Results

Hemoglobin A1c was significantly lower during incretin vs metreleptin treatment (mean difference −1.1 ± 0.4%, range −4.75% to −0.1%, P = .005), associated with modest weight reduction (mean difference −1.5 ± 3.9 kg, range −10.4 to 3 kg, P = .046). Most other metabolic parameters did not differ significantly between treatment periods.

Conclusion

In patients with partial lipodystrophy, incretins may provide better diabetes control than metreleptin, with comparable control of other metabolic parameters.

Schlagwörter

Stichwörter der Autor:innen

diabetesincretin receptor agonistsleptinpartial lipodystrophy

Autor:innen und Institutionen

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Brandon M Podyma, Rebecca J Brown

Förderung

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Zitieren

APA

Podyma, B. M., Lightbourne, M., & Brown, R. J. (2026). Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study. Journal of the Endocrine Society, 10(12). https://doi.org/10.1210/jendso/bvag248

Vancouver

Podyma BM, Lightbourne M, Brown RJ. Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study. Journal of the Endocrine Society. 2026;10(12). doi:10.1210/jendso/bvag248

BibTeX
@article{Podyma2026,
  author = {Podyma, Brandon M and Lightbourne, Marissa and Brown, Rebecca J},
  title = {Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study},
  journal = {Journal of the Endocrine Society},
  year = {2026},
  volume = {10},
  number = {12},
  doi = {10.1210/jendso/bvag248}
}
Kostenlos starten →